Maxygen’s Neutropenia Candidate Shows Positive Results In Phase IIa Trial
This article was originally published in The Pink Sheet Daily
Firm speculates drug could grab 20 percent to 50 percent of Neulasta’s market share.
You may also be interested in...
$24.5 million-plus licensing deal complements Sanofi’s vaccine work with Maxygen’s technology and could lead to next-generation dengue vaccine, Sanofi tells “The Pink Sheet” DAILY.
End of Roche relationship has no financial impact on Maxygen, which plans an update on unpartnered Phase II neutropenia candidate MAXY-G34 for early 2008, firm tells “The Pink Sheet” DAILY.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.